Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2026-03-01 @ 1:44 PM
Study NCT ID:
NCT03708432
Status:
COMPLETED
Last Update Posted:
2024-02-26
First Post:
2018-10-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
500mg Fulvestrant in HR+ MBC
Sponsor:
Fudan University
Organization:
Study Overview
Official Title:
An Observational, Retrospective Study of 500mg Fulvestrant in Hormone Receptor+/HER2- Advanced Breast Cancer
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the real world use of 500mg Fulvestrant in HR+ MBC.
Detailed Description:
An observational, retrospective study of 500mg Fulvestrant in hormone receptor+/HER2- advanced breast cancer
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: